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Background: Data comparing two bronchodilators vs. one bronchodilator plus inhaled cortico-
steroid (ICS) on hyperinflation and exercise endurance in chronic obstructive pulmonary
disease (COPD) are scarce, though these therapeutic strategies are widely used in clinical
practice.
Methods: We performed a randomized, crossover clinical trial of two  8 weeks comparing tio-
tropium (18 mg once daily) þ salmeterol (50 mg twice daily) (T þ S) to salmeterol þ fluticasone
(50/500 mg twice daily) (S þ F) in COPD (forced expiratory volume in 1 s (FEV1) 65% predicted,
and thoracic gas volume (TGV) 120% predicted). Coprimary endpoints were postbronchodila-
tor TGV and exercise endurance time (EET).
Results: In 309 patients, at baseline, prebronchodilator FEV1 was 1.36 L (46% predicted), TGV
was 5.42 L (165% predicted), and EETZ 458 s. Relative to S þ F, T þ S lowered postdose TGV by
182  44 ml after 4 weeks (p < 0.0001) and 87  44 ml after 8 weeks (p < 0.05). EET was
nonsignificantly increased following T þ S treatment (20  15 s at 4 weeks, 15  13 s at 8
weeks) vs. S þ F. BORG dyspnea score at exercise isotime was reduced in favor of T þ S.
Conclusion: The two bronchodilators decreased hyperinflation significantly more than one
bronchodilator and ICS. This difference was not reflected in EET.
(ClinicalTrials.gov number, NCT00530842)
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guidelines1 recommend combination maintenance medica-
tion in chronic obstructive pulmonary disease (COPD) when
single agents are not sufficiently effective. Long-acting
bronchodilators reduce symptoms and exacerbations, and
improve health status.2,3 However, many patients on single
medication remain symptomatic. In this situation, the
choice lies between a combination of different classes of
long-acting bronchodilators4,5 and the addition of an
inhaled corticosteroid (ICS) to a long-acting bronchodi-
lator.6 Data from randomized studies to inform the best
approach are scarce. In one study, a combination of bron-
chodilators was superior to a long-acting b2-agonist (LABA)/
ICS combination in improving resting lung function.7
Lung hyperinflation and exercise endurance are impor-
tant functional parameters that are related to the clinical
status of patients with COPD. It is unknown whether the
addition of a second bronchodilator instead of ICS results in
improved lung hyperinflation and exercise tolerance.
The Optimal Combination Treatment ANd Exercise
(OCTANE) study tested whether the free combination of
tiotropium þ salmeterol (T þ S) improves lung hyperinfla-
tion and exercise endurance time (EET) more than a fixed
combination of salmeterol þ fluticasone (S þ F) over 8
weeks in patients with COPD, in seven countries.Methods
Study design
This was a double-blind, multicenter (40 sites across seven
countries), randomized, double-dummy, crossover trial
involving patients with moderate to very severe COPD. The
coprimary endpoints were thoracic gas volume (TGV) and
EET after 8 weeks’ treatment with T þ S or S þ F. Secondary
endpoints included other lung function parameters, symp-
toms during exercise, reasons for exercise termination, and
safety parameters. For details on blinding and administra-
tion of the study drugs see e-appendix 1.
Concomitant respiratory medication (oral theophyllines
and mucolytics but no bronchodilators) was permitted in
patients if stabilized for at least 6 weeks prior to and
throughout the study. Open-label salbutamol (metered-
dose inhaler: 100 mg/actuation) was provided as rescue
medication during run-in and treatment periods, but was
withheld 8 h before each visit.
Study subjects
Patients with clinically stable COPD, aged 40e75 years with
a smoking history of 10 pack-years, prebronchodilator
forced expiratory volume in 1 s (FEV1) 65% predicted and
body plethysmographic TGV 120% predicted were
included. Key exclusion criteria were: significant diseases
other than COPD; history of asthma, allergic rhinitis, or
atopy; contraindications to clinical exercise testing
according to the American Thoracic Society/American
College of Chest Physicians8; exercise limitation unrelatedrehabilitation program within 6 weeks prior to screening.
The study was performed according to International
Conference on Harmonisation Good Clinical Practice
guidelines and the Declaration of Helsinki and was
approved by the Medical Ethics Committees of all 40
participating sites. Patients gave written informed consent.
Procedures
Patient eligibility was assessed during an initial screening
visit (day e15, visit 1). Patients performed pulmonary
function tests (PFTs) and a symptom-limited incremental
cycle exercise test to determine peak exercise capacity
(Wpeak). At visit 2 (day e5), eligible patients familiarized
themselves with testing procedures and a standardized
training history was established. PFTs were followed by
a constant-load cycle exercise test at 75% Wpeak. If the
exercise duration time exceeded 15 min, exercise workload
was increased to 90% Wpeak for subsequent tests.
On day 1 (visit 3), patients were randomized in a 1:1
ratio to a 56-day treatment period with either 18 mg tio-
tropium (SPIRIVA, Boehringer Ingelheim International
GmbH, Ingelheim, Germany) once daily in the morning, plus
50 mg salmeterol twice daily or the fixed S þ F combination,
twice daily (50/500 mg). A centralized randomization of
four blocks stratified according to sites was used. On day 1,
before study medication inhalation, PFTs were performed
followed by a constant-load cycle exercise test. Patients
whose exercise duration exceeded 15 min were excluded.
These test results served as baseline for both treatment
periods. On days 29 (after 4 weeks of period 1, visit 4), 57
(end of period 1, visit 5), 85 (after 4 weeks of period 2, visit
6), and 113 (end of period 2, visit 7), before (“trough”) and
80 min after study medication dosing, PFTs were per-
formed, followed by a constant-load exercise test (135 min
after dosing). All visits were conducted at a similar time in
the morning.
Quality control was ensured by performing practice tests
for pulmonary function and exercise testing at site initia-
tion visits, source data verification performed at each
center, and careful review of data quality prior to
unblinding.
Pulmonary function testing
PFTs were conducted in accordance with recognized stan-
dards.9,10 TGV, residual volume, inspiratory capacity,
inspiratory reserve volume, and total lung capacity (TLC)
were measured during body plethysmography followed by
spirometric tests: FEV1, forced vital capacity (FVC), and
slow vital capacity measurements were performed in trip-
licate and the best values were used for analysis.
Exercise testing
Symptom-limited incremental and constant-load cycle
exercise testing procedures have been described pre-
viously11e13 and are detailed in e-appendix 2. The locus of
symptom limitation at the end of exercise was recorded as
Figure 1 Patient flow during study. *One patient completed
period 1 according to protocol but discontinued before starting
period 2 medication due to administrative reasons.
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or neither dyspnea or leg discomfort.
Medication restrictions for exercise/PFTs
Respiratory medication was withheld for appropriate time
spans (see e-appendix 3).
Safety
Adverse events (AEs), serious AEs and deaths were recorded
for both treatments.
Statistical analysis
For both postdose TGV and EET after 8 weeks’ crossover
treatment of patients with both investigational combina-
tion drugs, the null hypothesis was that there is no differ-
ence in the effect between treatment with T þ S and S þ F.
The alternative hypothesis was that there is a difference in
the effect between treatments.
The null hypothesis for postdose TGV after 8 weeks’
investigational treatment was tested using analysis of
variance with fixed terms for sequence, treatment and
period, and random term for patient within sequence. If
this resulted in a statistically significant difference, EET
after 8 weeks’ investigational treatment was tested using
Wilcoxon’s signed rank test. This procedure required no
adjustment in significance level for multiple testing, i.e.,
both tests were performed at a Z 0.05. For this test
procedure and a significance level of 0.05, a sample size of
294 analyzable patients was estimated to yield a power of
at least 86% for the primary analysis. This calculation was
based on experience from earlier active- and placebo-
controlled studies, and accounted for the nonparametrical
testing of EET. After correction for potential dropouts,
randomization of 368 patients was planned. No corrections
for multiple hypotheses testing were made for secondary
endpoints; these analyses were exploratory and the results
were interpreted in a descriptive manner. All tests were
two-sided with a Z 0.05.
For efficacy analyses, the intention-to-treat principle
was used to include as many patients as possible. All
patients with any postdosing TGV or EET efficacy data after
at least 4 weeks for both treatments were included in the
full analysis set (nZ 309). Missing data were imputed based
on rules defined prior to unblinding. All patients who
received at least one dose of study medication were
included in the safety analysis (n Z 344).
Results
Study population
Patients were recruited from September 2007 to September
2008. A total of 344 patients were randomized and received
at least one dose of trial medication: 172 received T þ S
and 172 received S þ F in the first treatment period; 157
patients received S þ F and 160 patients received T þ S in
the second treatment period (Fig. 1). Patients in the twotreatment sequences (T þ S followed by S þ F and vice
versa) were generally well matched at baseline. Mean age
was 61 years, 71.8% were men, and 43.6% current smokers.
Prebronchodilator FEV1 at baseline was 46.5% of predicted
normal with reversibility (30 min after inhalation of four
puffs salbutamol) of 13.1% of prebronchodilator value;
54.1% of patients had a postbronchodilator FEV1 50%
predicted. Patients were moderately hyperinflated (TGV,
165% predicted) (Table 1).
Efficacy
Thoracic gas volume
Adjusted mean TGV (nZ 309) decreased from 5.46  0.07 L
at baseline to 5.00  0.07 L and 4.99  0.07 L after 4 and 8
weeks’ T þ S treatment, respectively. Respective values
with S þ F were 5.18  0.07 L and 5.07  0.07 L (Fig. 2). The
reduction in postdose TGV was significantly greater after
T þ S compared with S þ F, with differences between
groups of 182  44 ml (p < 0.0001) after 4 weeks and
87  44 ml (p < 0.05) after 8 weeks. Results according to
treatment sequence are shown in e-figure 1.
Other lung volumes and spirometric parameters
For the secondary lung function endpoints, all postdose
measurements after 8 weeks reached nominal statistical
significance in favor of T þ S except for TLC (Table 2).
Table 1 Patient characteristics at study entry for treated patients.
Sequence T þ S/ S þ F (n Z 172) S þ F/ T þ S (n Z 172) Overall (n Z 344)
Age, years 61.5  7.5 60.6  7.6 61.0  7.6
Male, % 72.1 71.5 71.8
Current smoker, % 39.0 48.3 43.6
COPD duration, years 8.2  6.3 7.9  5.7 8.0  6.0
Body mass index, kg/m2 26.5  5.1 26.5  4.7 26.5  4.9
Blood eosinophils, 1/mm3 208.4  135.2 197.3  120.7 202.9  128.1
LABA user, % 48.3 45.9 47.1
ICS user, % 45.3 39.5 42.4
Tiotropium#, % 20.9 24.4 22.7
Lung function parameter*
FEV1, L 1.38  0.43 1.35  0.41 1.36  0.42
FEV1 % predicted 47  12 46  12 47  12
FVC, L 2.84  0.72 2.87  0.80 2.86  0.76
FVC, % predicted 78  16 78  17 78  17
FEV1/FVC, % 49.2  11.8 48.2  12.1 48.7  12.0
Reversibility, post/pre, %** 12.2  12.8 13.9  13.1 13.1  12.9
TGV, % predicted 163  34 167  38 165  36
RV, % predicted 195  52 200  59 197  56
TLC, % predicted 119  19 120  21 120  20
Exercise testing at baseline*
Endurance time 451  200 464  197.3 458  198
Work rate, Watt 64  21 68  25 66  23
Values are means  standard deviation unless otherwise specified.
T þ S, tiotropium þ salmeterol; S þ F, salmeterol þ fluticasone; COPD, chronic obstructive pulmonary disease; LABA, long-acting b-
agonist; ICS, inhaled corticosteroid; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; TGV, thoracic gas volume; RV,
residual volume; TLC, total lung capacity.
#Discontinued 4 weeks before screening period and substituted by ipratropium; *Measured at visit 3 (day of randomization); **Measured
at visit 2, following salbutamol 200 mg.
Figure 2 Mean change in postdose TGV (standard error)
over 8 weeks vs. baseline for T þ S (solid line) and S þ F
(dashed line). Trough was measured in the morning before
inhalation and postdose 80 min after inhalation of study drugs.
TGV, thoracic gas volume; T þ S, tiotropium þ salmeterol;
S þ F, salmeterol þ fluticasone.
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253  16 ml and FVC by 395  28 ml after 8 weeks with
T þ S. Treatment differences vs. S þ F were 71  14 ml for
FEV1 and 154  24 ml for FVC in favor of T þ S (p < 0.0001)
(Fig. 3A and B).
Exercise endurance time
Mean EET (n Z 309) at baseline was 460  11 s and
increased in patients treated with T þ S by 93  17 s after 4
weeks and by 97  18 s after 8 weeks. Respective values for
S þ F were 73  14 s after 4 weeks and 82  16 s after 8
weeks. Median and mean differences between groups were
not statistically significant, although mean values were
15  13 s higher at 8 weeks and 20  15 s higher at 4 weeks
with T þ S (Fig. 4). Results according to treatment
sequence are shown in e-figure 2.
Symptoms during exercise
Dyspnea at isotime during constant workload exercise was
5.73  0.14 Borg units at baseline, 4.80  0.12 after 4
weeks and 4.77  0.13 after 8 weeks with T þ S. Results
were in favor of T þ S at 4 weeks (0.23  0.11 units;
p < 0.05) and at 8 weeks (0.21  0.11 units; p Z 0.07).
Neither treatment significantly changed leg discomfort at
isotime (all values  0.3 units vs. baseline).
At baseline, 42.7% of the patients indicated dyspnea
(breathing discomfort) as the primary reason for stopping
exercise. After 8 weeks’ T þ S treatment, dyspnea was the
Table 2 Lung function parameters after 4 and 8 weeks’
treatment with T þ S and S þ F.
T þ S minus S þ F (ml) p-values
Trough Postdose Trough/postdose
FEV1
Week 4 38  14 68  12 0.0068/<0.0001
Week 8 36  14 71  14 0.0115/<0.0001
FVC
Week 4 110  23 140  22 <0.0001/<0.0001
Week 8 116  23 154  24 <0.0001/<0.0001
SVC
Week 4 71  26 116  28 0.0062/<0.0001
Week 8 102  27 138  27 0.0002/<0.0001
TGV
Week 4 22  49 182  44 0.6458/<0.0001
Week 8 18  56 87  44 0.7466/0.0482
RV
Week 4 69  52 234  51 0.1822/<0.0001
Week 8 26  60 154  47 0.6622/0.0011
IC
Week 4 55  30 97  39 0.0675/0.0136
Week 8 98  34 115  33 0.0039/0.0005
IRV
Week 4 45  30 70  38 0.1384/0.0699
Week 8 65  30 67  32 0.0324/0.0381
TLC
Week 4 12  50 138  52 0.8055/0.0082
Week 8 76  60 0  47 0.2114/0.9944
Values displayed are adjusted mean treatment differences.
Trough was measured in the morning before inhalation and
postdose 80 min after inhalation of study drugs. Values are
means  standard error. T þ S, tiotropium þ salmeterol; S þ F,
salmeterol þ fluticasone; FEV1, forced expiratory volume in 1 s;
FVC, forced vital capacity; SVC, slow vital capacity; TGV,
thoracic gas volume; RV, residual volume; IC, inspiratory
capacity; IRV, inspiratory reserve volume; TLC, total lung
capacity.
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whereas no change occurred after S þ F (42.4% of patients).
The shift from “dyspnea” to “leg discomfort” after 8 weeks
was statistically significant for both treatment groups
(p < 0.05), however the difference was significantly larger
with T þ S than S þ F (p Z 0.0056) (Fig. 5).
The impact of treatments on exercise duration was
influenced by the locus of symptom limitation. Patients
with “dyspnea” as the main reason for stopping exercise
had a mean increase from baseline in EET of 137  27 s
after 8 weeks with T þ S. For “dyspnea and leg discomfort”
and for “leg discomfort” the corresponding improvements
were 111  41 s and 52  28 s, respectively (Fig. 6).
AEs
The most common AEs were COPD exacerbation, headache,
and nasopharyngitis. COPD exacerbations occurred in 29
patients (8.7%) with T þ S and in 24 patients (7.3%) with
S þ F. Respectively, three and nine patients complained of
headache during T þ S and S þ F; for nasopharyngitis, thecorresponding numbers were 14 and 15. No deaths occurred
during treatment. During T þ S treatment, 30.7% of
patients experienced an AE; 3.6% were considered serious.
The corresponding percentages for S þ F were 31.9% and
2.4%, respectively. None of the serious AEs were deemed
related to study drugs. No clinically significant AEs related
to exercise testing were reported.Discussion
The present study demonstrates that T þ S treatment in
moderate to severe COPD patients reduces lung hyperin-
flation significantly more than S þ F, whereas EET was not
significantly different between the two treatments. The
reduction in exertional dyspnea was greater with T þ S than
S þ F, and a shift in the locus of symptom limitation from
dyspnea to leg discomfort was seen in a greater proportion
of patients during T þ S than S þ F treatment.
In several placebo-controlled studies, T þ S treatment
resulted in a significant decrease in hyperinflation and
improvement in EET.11,12,14 Other randomized, double-
blind studies demonstrated that two long-acting broncho-
dilators were more effective in improving spirometry than
a single long-acting bronchodilator.4,5,15 Combining S þ F
produces some benefits on spirometric parameters
compared to salmeterol alone.6
We have confirmed that T þ S was more effective in
reducing hyperinflation and improving expiratory flows than
S þ F. The maximal effect of T þ S was already observed
after 4 weeks as opposed to 8 weeks with S þ F. While
bronchodilation after tiotropium þ formoterol,4,5 or T þ S15
is more pronounced than without LABA, the progressive
improvement of hyperinflation between week 4 and 8 after
S þ F is more difficult to explain. A recent study demon-
strated that budesonide þ formoterol had a better effect
on hyperinflation and EET than formoterol alone,16 indi-
cating that ICS may mediate the beneficial effects of LABA,
but a similar study looking at how ICS alone affects
hyperinflation and EET is lacking. Alternatively, maximal
bronchodilation may be achieved after 4 weeks with two
bronchodilators but not a single bronchodilator, thereby
diminishing the between-treatment difference after 8
weeks. Long-term improvements with one long-acting
bronchodilator in poor initial responders have been
described17 but time-to-peak effect was not determined.
The present study is consistent with other reports asso-
ciating reductions in hyperinflation with EET improve-
ments.11,12 We demonstrated that both therapeutic
regimens significantly improved EET but no significant
differences in EETwere substantiated between treatments,
despite differences in static hyperinflation. This may indi-
cate that other factors (i.e., peripheral muscles, motiva-
tion) are involved in determining exercise duration in
certain COPD patients. The increase in the exercise dura-
tion of 75e105 s vs. baseline during a moderately strenuous
task with study medication is clinically meaningful and
aligned with other data from pharmacologic and non-
pharmacologic interventions.18e20
Constant work rate at a high level of individual work
capacity leads to increasing dyspnea and leg discomfort, or
exercise cessation.21 Reductions in dyspnea at a given work
Figure 3 A and B Mean change in FEV1 and FVC (standard error) vs. baseline for T þ S (solid line) vs. S þ F (dashed line). Trough
was measured in the morning before inhalation and postdose 80 min after inhalation of study drugs. FEV1, forced expiratory volume
in 1 s; FVC, forced vital capacity; T þ S, tiotropium þ salmeterol; S þ F, salmeterol þ fluticasone.
1418 H. Magnussen et al.rate or exercise duration may result in two outcomes:
longer exercise time or a shift in the locus of symptom
limitation (preventing longer exercise time).22 In this study,
a strong shift from breathing discomfort to leg discomfortFigure 4 Mean change in postdose EET (standard error) vs.
baseline (trough) for T þ S (solid line) and S þ F (dashed line).
Trough was measured in the morning before inhalation and
postdose 135 min after inhalation of study drugs. EET, exercise
endurance time; T þ S, tiotropium þ salmeterol; S þ F,
salmeterol þ fluticasone.resulting in exercise cessation was observed with T þ S,
suggesting an inability to increase EET due to leg discom-
fort. A significant EET increase was observed in a study with
COPD patients performing treadmill exercise23 when phar-
macologic treatment was combined with a physical training
program. Whether training in conjunction with treadmill
exercise would produce larger differences in EET between
dual bronchodilator therapy and bronchodilator þ ICS
therapy is unknown. Treadmill exercise or other forms of
walking was recently described as more suitable for exer-
cise testing as it involves less frequent leg fatigue as the
limiting symptom.23e26
This study has several limitations. As with most studies
involving exercise endurance evaluation in COPD, this study
was relatively short and does not address long-term bene-
fits, including quality of life and formal evaluations of COPD
exacerbations. The study did not include a placebo control,
as we were interested in the difference between clinically
approved therapeutic options that are in international
guidelines. Finally, patients were not specifically selected
for requiring two maintenance treatments.
The safety assessment was generally consistent with the
known safety profile of tiotropium27 and the other study
drugs. No clinically relevant AEs were identified during
more than 2000 exercise tests, confirming that exercise
testing is an appropriate procedure in moderate to very
severe COPD patients.11,12 Furthermore, tiotropium was
used safely in combination with salmeterol in patients who
were exercising strenuously. This is especially important
because exercise is one of the core treatment options
recommended for long-term COPD therapy.
In conclusion, the combination of two long-acting
bronchodilators leads to decreased hyperinflation
(improvement in lung function) in moderate to very severe
COPD patients relative to a long-acting bronchodilator in
Figure 5 Proportion of patients giving “Dyspnea” or “Leg
discomfort” or both as main reason for stopping the exercise
test after 8 weeks’ treatment compared to baseline in the
T þ S- vs. S þ F-treated patients. #Shift in locus of symptom
limitation vs. baseline from dyspnea to leg was significant for
both treatments (p < 0.05). *Significant shift in locus of
symptom limitation from dyspnea to leg between treatments
(p Z 0.0056, Wilcoxon signed rank test) in favor of T þ S. The
proportion of patients with “other reasons” for stopping
exercise at baseline was 10.4% and did not change appreciably
during active treatment (8.7% for T þ S, 9.1% for S þ F); data
not shown within the figure.
Effect of combination treatment in COPD 1419combination with an ICS. Although the EET was not signifi-
cantly different between treatment groups, patients
receiving two long-acting bronchodilators experienced lessFigure 6 Mean change in postdose EET after 8 weeks’
treatment vs. baseline (trough) with T þ S (-) or S þ F (,)
depending on reason for stopping exercise at baseline. Patients
with “other reasons” for stopping exercise at baseline (nZ 32)
had decreased exercise time during active treatment (36 for
T þ S and 39.2 for S þ F); data not shown within the figure.dyspnea and were less likely to stop exercise because of
breathlessness.
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